학술논문
In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines.
Document Type
Article
Author
Baldini, Enke; Presutti, Dario; Favoriti, Pasqualino; Santini, Simonetta; Papoff, Giuliana; Tuccilli, Chiara; Carletti, Raffaella; Di Gioia, Cira; Lori, Eleonora; Ferent, Iulia Catalina; Gagliardi, Federica; Catania, Antonio; Pironi, Daniele; Tripodi, Domenico; D'Andrea, Vito; Sorrenti, Salvatore; Ruberti, Giovina; Ulisse, Salvatore
Source
Subject
*ANAPLASTIC thyroid cancer
*PLASMINOGEN activator inhibitors
*UROKINASE
*CELL lines
*PLASMINOGEN activators
*THYROID gland
*CELL adhesion
*
*
*
*
*
*
Language
ISSN
1661-6596
Abstract
Increased expression of the urokinase-type plasminogen activator (uPA) system is associated with tumor invasion, neo-angiogenesis, and metastatic spread, and has been shown to positively correlate with a poor prognosis in several cancer types, including thyroid carcinomas. In recent years, several uPA inhibitors were found to have anticancer effects in preclinical studies and in some phase II clinical trials, which prompted us to evaluate uPA as a potential therapeutic target for the treatment of patients affected by the most aggressive form of thyroid cancer, the anaplastic thyroid carcinoma (ATC). In this study, we evaluated the in vitro and in vivo effects of WX-340, a highly specific and selective uPA inhibitor, on two ATC-derived cell lines, CAL-62 and BHT-101. The results obtained indicated that WX-340 was able to reduce cell adhesion and invasiveness in a dose-dependent manner in both cell lines. In addition, WX-340 increased uPA receptor (uPAR) protein levels without affecting its plasma membrane concentration. However, this compound was unable to significantly reduce ATC growth in a xenograft model, indicating that uPA inhibition alone may not have the expected therapeutic effects. [ABSTRACT FROM AUTHOR]